MGC Pharmaceuticals Limited (MGCLF)
MGC Pharmaceuticals Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in West Perth, WA, AU. The stock last traded at $0.27, up 2.88% on the session, giving a market capitalisation of $12.1M. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of -614.6%. Its beta of 0.97 implies it has historically moved less than the broad market.
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
MGC Pharmaceuticals Limited is most often compared with the following Healthcare names: